Advertisement
JNJ or MRK or PFE
Which Stock Would AI Choose? Johnson & Johnson (JNJ) vs. Merck & Co. (MRK) vs. Pfizer Inc. (PFE) Stock Comparison
Key Takeaways
- JNJ leads with strong YTD gains around 14%, bolstered by FDA approvals like ICOTYDE for psoriasis and oncology pipeline expansions, despite talc litigation headwinds.
- MRK shows solid YTD performance near 9%, driven by Keytruda's dominance but facing Gardasil sales softness and looming 2028 patent cliffs.
- PFE trails with modest YTD upticks around 8%, supported by RSV vaccine Abrysvo growth amid declining COVID product demand and patent pressures.
- All three exhibit defensive traits with low betas under 0.4, attractive dividend yields (JNJ 2.2%, MRK 3.0%, PFE 6.4%), and P/E ratios in the 15-21x range, appealing for relative stability in volatile markets.
- Recent momentum favors JNJ amid pipeline catalysts, while MRK and PFE grapple with exclusivity losses.
- Sector resilience shines as healthcare outperforms broader indices, positioning these stocks for income-focused portfolios.
Introduction
Johnson & Johnson (JNJ), Merck & Co. (MRK), and Pfizer Inc. (PFE) represent cornerstone players in the pharmaceutical sector, renowned for diversified portfolios spanning oncology, vaccines, and innovative medicines. This stock comparison evaluates their recent market positioning, performance drivers, and risk profiles amid evolving healthcare dynamics like patent transitions and regulatory milestones. Traders seeking momentum and investors prioritizing dividends or stability will find value in dissecting their relative strengths, as these blue-chips navigate sector tailwinds such as aging demographics and pipeline advancements while contending with exclusivity losses.
JNJ Overview and Recent Performance
Johnson & Johnson (JNJ), a global healthcare leader, operates through Innovative Medicine and MedTech segments, delivering pharmaceuticals, medical devices, and consumer health solutions. In recent market activity, JNJ shares traded around $235, reflecting YTD gains of approximately 14% and a 44% one-year rise, outpacing the S&P 500. This resilience stems from robust pipeline progress, including FDA approval for ICOTYDE, an oral plaque psoriasis treatment, and oncology expansions via collaborations. Sentiment has been tempered by ongoing talc litigation setbacks, such as a judge overturning a $950 million punitive award, alongside Stelara's patent exclusivity loss. Nonetheless, analysts like Citi and BofA have raised price targets, citing pipeline strength and projected 2026 earnings growth of 7%, underscoring JNJ's defensive appeal with a 2.2% dividend yield and P/E of 21x.
MRK Overview and Recent Performance
Merck & Co. (MRK), a biopharma powerhouse, excels in oncology, vaccines, and hospital care, with Keytruda as its cornerstone generating over $30 billion annually. Shares hovered near $114 in recent weeks, posting YTD returns around 9% and 21% over one year, amid broader healthcare volatility. Performance reflects Keytruda's sustained demand despite 2028 patent concerns, offset by Gardasil sales slumps prompting layoffs and restructuring into separate oncology and specialty units. Positive catalysts include new approvals and acquisitions bolstering the pipeline, though generics loom for legacy products. With a 3.0% dividend yield, P/E of 16x, and analyst upgrades like Citi's $125 target, MRK maintains momentum through oncology leadership and projected revenue stability.
PFE Overview and Recent Performance
Pfizer Inc. (PFE) focuses on biopharma innovation, with strengths in oncology, vaccines, and rare diseases post-Seagen acquisition. Trading around $27 lately, PFE shares have advanced about 8% YTD and 3% over one year, lagging peers amid post-COVID normalization. Key drivers include RSV vaccine Abrysvo's surge, exceeding expectations at $481 million in recent quarterly sales, and oncology expansions like Talzenna. Headwinds persist from declining Comirnaty/Paxlovid demand and 2026 revenue guidance of $59.5-62.5 billion, factoring $1.5 billion COVID drops and LOE impacts. Offering a compelling 6.4% dividend yield and P/E near 20x, PFE's non-COVID growth of 6% operationally signals recovery potential for value-oriented investors.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top 25 AI trading bots curated from over 350 available on the platform, which collectively trade thousands of tickers across diverse strategies. These bots employ varied approaches like swing trading, trend following, hedging, and multi-agent systems on timeframes from 5 minutes to 60 minutes, leveraging technical, fundamental, and AI/ML analyses. Standout performers include bots with annualized returns up to 188%, win rates from 55% to 89%, and profit factors reaching 6.11, such as those targeting energy booms (+63%), semiconductors (+90-99%), and volatility plays. Selected for excellence in current conditions—low, medium, or high volatility—these bots suit aggressive growth seekers or conservative hedgers. Explore Trending AI Robots to identify strategies aligning with your risk profile and market outlook.
Head-to-Head Comparison
JNJ, MRK, and PFE share healthcare sector exposure but diverge in business models: JNJ's diversified Innovative Medicine and MedTech balance pharma risks, unlike MRK's oncology/vaccine focus and PFE's post-COVID pivot to RSV/oncology. Growth drivers highlight MRK's Keytruda dominance versus JNJ's Darzalex/Tremfya and PFE's Abrysvo. Recent momentum favors JNJ (14% YTD) over MRK (9%) and PFE (8%). Risks include JNJ's talc suits/Stelara LOE, MRK's Keytruda 2028 cliff/Gardasil weakness, and PFE's COVID decline. Valuation sensitivity shows MRK cheapest at 16x P/E, PFE at 20x with highest yield (6.4%), versus JNJ's 21x premium for stability. Market sentiment leans toward JNJ's consistency amid peers' transitions.
Tickeron AI Verdict
Tickeron’s AI currently favors JNJ based on superior trend consistency, YTD outperformance, and balanced catalysts like ICOTYDE approval offsetting litigation risks. Its lower beta, diversified model, and analyst-upgraded targets suggest higher probability of relative gains versus MRK's patent overhang and PFE's COVID normalization, though all warrant monitoring for pipeline execution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 3 FA rating(s) are green whileMRK’s FA Score has 4 green FA rating(s), and PFE’s FA Score reflects 1 green FA rating(s).
- JNJ’s FA Score: 3 green, 2 red.
- MRK’s FA Score: 4 green, 1 red.
- PFE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 1 TA indicator(s) are bullish while MRK’s TA Score has 4 bullish TA indicator(s), and PFE’s TA Score reflects 3 bullish TA indicator(s).
- JNJ’s TA Score: 1 bullish, 6 bearish.
- MRK’s TA Score: 4 bullish, 4 bearish.
- PFE’s TA Score: 3 bullish, 5 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а -1.88% price change this week, while MRK (@Pharmaceuticals: Major) price change was +0.46% , and PFE (@Pharmaceuticals: Major) price fluctuated -4.94% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.86%. For the same industry, the average monthly price growth was -2.62%, and the average quarterly price growth was +6.54%.
Reported Earning Dates
JNJ is expected to report earnings on Apr 14, 2026.
MRK is expected to report earnings on Apr 30, 2026.
PFE is expected to report earnings on May 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.86% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| JNJ | MRK | PFE | |
| Capitalization | 574B | 300B | 153B |
| EBITDA | 41.1B | 28.3B | 16.8B |
| Gain YTD | 15.838 | 16.207 | 9.923 |
| P/E Ratio | 21.62 | 16.68 | 19.79 |
| Revenue | 94.2B | 65B | 62.6B |
| Total Cash | 20.1B | N/A | 13.6B |
| Total Debt | 47.9B | 49.3B | 64B |
JNJ | MRK | PFE | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 59 | 59 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 22 Undervalued | 23 Undervalued | 33 Fair valued | |
PROFIT vs RISK RATING 1..100 | 9 | 45 | 100 | |
SMR RATING 1..100 | 27 | 25 | 73 | |
PRICE GROWTH RATING 1..100 | 42 | 16 | 35 | |
P/E GROWTH RATING 1..100 | 78 | 25 | 34 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 32 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (22) in the Pharmaceuticals Major industry is in the same range as MRK (23) and is in the same range as PFE (33). This means that JNJ's stock grew similarly to MRK’s and similarly to PFE’s over the last 12 months.
JNJ's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (45) and is significantly better than the same rating for PFE (100). This means that JNJ's stock grew somewhat faster than MRK’s and significantly faster than PFE’s over the last 12 months.
MRK's SMR Rating (25) in the Pharmaceuticals Major industry is in the same range as JNJ (27) and is somewhat better than the same rating for PFE (73). This means that MRK's stock grew similarly to JNJ’s and somewhat faster than PFE’s over the last 12 months.
MRK's Price Growth Rating (16) in the Pharmaceuticals Major industry is in the same range as PFE (35) and is in the same range as JNJ (42). This means that MRK's stock grew similarly to PFE’s and similarly to JNJ’s over the last 12 months.
MRK's P/E Growth Rating (25) in the Pharmaceuticals Major industry is in the same range as PFE (34) and is somewhat better than the same rating for JNJ (78). This means that MRK's stock grew similarly to PFE’s and somewhat faster than JNJ’s over the last 12 months.
| JNJ | MRK | PFE | |
|---|---|---|---|
| RSI ODDS (%) | N/A | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 52% | 1 day ago 52% | 1 day ago 61% |
| Momentum ODDS (%) | 1 day ago 47% | 1 day ago 52% | 1 day ago 54% |
| MACD ODDS (%) | 1 day ago 52% | 1 day ago 47% | 1 day ago 55% |
| TrendWeek ODDS (%) | 1 day ago 40% | 1 day ago 53% | 1 day ago 58% |
| TrendMonth ODDS (%) | 1 day ago 42% | 1 day ago 52% | 1 day ago 54% |
| Advances ODDS (%) | 3 days ago 44% | 10 days ago 52% | 11 days ago 56% |
| Declines ODDS (%) | 5 days ago 41% | 1 day ago 51% | 1 day ago 57% |
| BollingerBands ODDS (%) | N/A | 1 day ago 51% | 1 day ago 54% |
| Aroon ODDS (%) | 1 day ago 34% | 1 day ago 53% | 1 day ago 51% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DFE | 75.65 | 0.34 | +0.45% |
| WisdomTree Europe SmallCap Dividend ETF | |||
| SPDW | 48.19 | 0.10 | +0.21% |
| State Street® SPDR® Ptf Dev Wld exUS ETF | |||
| TOT | 21.34 | -0.04 | -0.17% |
| Lionshares U.S. Equity Total Return ETF | |||
| PSIL | 17.66 | -0.04 | -0.24% |
| AdvisorShares Psychedelics ETF | |||
| VFVA | 137.12 | -1.47 | -1.06% |
| Vanguard US Value Factor ETF | |||
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been closely correlated with PFE. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if MRK jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To MRK | 1D Price Change % | ||
|---|---|---|---|---|
| MRK | 100% | -1.03% | ||
| PFE - MRK | 67% Closely correlated | -1.10% | ||
| BMY - MRK | 64% Loosely correlated | -1.43% | ||
| BIIB - MRK | 59% Loosely correlated | -2.34% | ||
| AMGN - MRK | 57% Loosely correlated | -1.29% | ||
| ABBV - MRK | 56% Loosely correlated | -2.10% | ||
More | ||||
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been closely correlated with MRK. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if PFE jumps, then MRK could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -1.10% | ||
| MRK - PFE | 67% Closely correlated | -1.03% | ||
| BMY - PFE | 66% Closely correlated | -1.43% | ||
| BIIB - PFE | 64% Loosely correlated | -2.34% | ||
| AMGN - PFE | 61% Loosely correlated | -1.29% | ||
| NVS - PFE | 57% Loosely correlated | -0.65% | ||
More | ||||